ESSA PHARMA INC's ticker is EPIX and the CUSIP is 29668H708. A total of 41 filers reported holding ESSA PHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,080 | +162.8% | 12,000 | +129.7% | 0.00% | – |
| Q2 2023 | $14,107 | -9.1% | 5,225 | 0.0% | 0.00% | – |
| Q1 2023 | $15,518 | +19.4% | 5,225 | 0.0% | 0.00% | – |
| Q4 2022 | $13,000 | +62.5% | 5,225 | +23.7% | 0.00% | – |
| Q3 2022 | $8,000 | -38.5% | 4,225 | 0.0% | 0.00% | – |
| Q2 2022 | $13,000 | -50.0% | 4,225 | 0.0% | 0.00% | – |
| Q1 2022 | $26,000 | -60.0% | 4,225 | -7.3% | 0.00% | – |
| Q4 2021 | $65,000 | +27.5% | 4,559 | -28.8% | 0.00% | – |
| Q3 2021 | $51,000 | -92.3% | 6,401 | -72.4% | 0.00% | -100.0% |
| Q2 2021 | $662,000 | +3.8% | 23,165 | +5.6% | 0.00% | -50.0% |
| Q1 2021 | $638,000 | +282.0% | 21,945 | +56.8% | 0.00% | – |
| Q4 2020 | $167,000 | +153.0% | 14,000 | +47.4% | 0.00% | – |
| Q3 2020 | $66,000 | +11.9% | 9,500 | 0.0% | 0.00% | – |
| Q2 2020 | $59,000 | +73.5% | 9,500 | +11.8% | 0.00% | – |
| Q1 2020 | $34,000 | – | 8,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 4,223,799 | $26,103,000 | 3.37% |
| MPM BioImpact LLC | 660,892 | $4,084,000 | 1.10% |
| BVF INC/IL | 3,695,629 | $22,839,000 | 0.91% |
| Omega Fund Management, LLC | 328,196 | $2,028,000 | 0.42% |
| Eventide Asset Management | 4,170,259 | $25,772,000 | 0.40% |
| Frazier Life Sciences Management, L.P. | 692,910 | $4,282,000 | 0.36% |
| Bellevue Group AG | 5,034,814 | $31,115,000 | 0.36% |
| RTW INVESTMENTS, LP | 2,637,192 | $16,298,000 | 0.34% |
| Avidity Partners Management LP | 2,460,000 | $15,203,000 | 0.32% |
| Rhenman & Partners Asset Management AB | 410,923 | $2,540,000 | 0.25% |